Anticoagulant and antiplatelet medications — warfarin, apixaban, rivaroxaban, clopidogrel, aspirin — are a common feature of the pre-operative assessment for hair transplant surgery. The question of whether they can be continued, reduced, or stopped before the procedure requires careful consideration of both bleeding risk and the underlying reason the medication was prescribed.
Blood thinners are prescribed for good reasons — atrial fibrillation, deep vein thrombosis history, mechanical heart valves, stroke prevention. Stopping them carries real risks. This is not a decision to be made by the hair transplant surgeon alone, and any patient on these medications should ensure their prescribing physician is part of the pre-operative planning conversation.
For aspirin used purely as a general cardiovascular preventative (primary prevention) in lower-risk patients, a seven to ten day pause before surgery is often acceptable after discussion with the prescribing doctor. The evidence that aspirin meaningfully increases bleeding complications from FUE surgery is modest, but most surgeons prefer to have patients off it before a procedure.
For anticoagulants prescribed for active thromboembolic risk — particularly direct oral anticoagulants (DOACs) like apixaban — the decision is more complex. Bridging strategies, timing adjustments around dose cycles, and the specific coagulation profile of each medication are all relevant. These cases require a multidisciplinary approach.
For patients on warfarin, INR monitoring close to the procedure date is important. Most surgeons prefer an INR below 1.5 for the procedure. The decision to temporarily stop or adjust warfarin should be made jointly with the anticoagulation team.
Related reading
